Back to search
FDAFDA · Food and drugs·Recall number D-0478-2021

ADVAIR HFA 45-21MCG 12GM; NDC/UPC 173071520; RX; INHALER MEDICAL INTERNAL - MAY OR MAY NOT BE AEROSOL

Published June 2, 2021 · Recall initiated: March 15, 2021

Summary

FDA records drug Class II recall D-0478-2021, published June 2, 2021 and initiated March 15, 2021. Recalling firm: Cardinal Health Inc.; Status: Terminated; Reported quantity: 297 inhalers; Lot: TH4K. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Intermittent exposure to temperature excursion during storage.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Cardinal Health Inc.
Distributor
FL, GA, SC
Lot
TH4K
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was ADVAIR HFA 45-21MCG 12GM; NDC/UPC 173071520; RX; INHALER MEDICAL INTERNAL - MAY OR MAY NOT BE AEROSOL recalled?

Yes. FDA published recall D-0478-2021 on June 2, 2021. Reported hazard: CGMP Deviations: Intermittent exposure to temperature excursion during storage.

What should I do if I have this product?

Voluntary: Firm initiated · Letter